Eli Lilly & Co (LLY) DIvidends Date & History

Key Takeaways

• Eli Lilly pays a quarterly dividend of $1.73 per share, equal to an annualized $6.92 per share.
• The dividend yield is roughly 0.55%, well below the pharmaceutical industry average, reflecting a high share price rather than a small payout.
• Lilly has raised its dividend for 11 consecutive years, with roughly 15% annualized growth over the past five years.
• The payout ratio sits near 22% of earnings, leaving ample room for future increases.
• The stock is best suited to dividend growth investors rather than investors seeking immediate income.

Dividend Overview

Eli Lilly and Company is a global pharmaceutical leader known for treatments in diabetes, obesity, oncology, and immunology. While the company is a steady and reliable dividend payer, it is not a high-yield dividend stock. As of late 2026, LLY pays a quarterly dividend of $1.73 per share, translating to an annualized payout of $6.92 per share.

Because the share price has climbed sharply in recent years, the dividend yield is a modest 0.55%. Payments are made quarterly, a schedule consistent with most large-cap pharmaceutical peers. Rather than functioning as a high-yield income vehicle, Lilly is more accurately described as a dividend growth stock: a company whose payout is modest on a yield basis but grows rapidly over time as earnings expand.

Dividend History and Growth

Lilly has a long record of returning cash to shareholders and has increased its dividend for 11 consecutive years. The growth rate has been notable: the company has raised its dividend by roughly 15% annually over the past five years, a pace that stands out within the large-cap healthcare sector.

The most recent increase took the quarterly payout from $1.50 to $1.73 per share, a rise of about 15.3%. Over the longer term, the annual dividend per share has climbed from $3.92 in 2023 to $5.20 in 2024 and $6.00 in 2025, with trailing twelve-month dividends reaching about $6.69 in 2026. This steady, above-average growth reflects both strong earnings momentum and management's commitment to sharing profits with shareholders while continuing to reinvest in research and development.

Dividend Sustainability and Payout Ratio

Lilly's dividend appears highly sustainable. The company's payout ratio — the share of earnings paid out as dividends — is approximately 22%, which is low by pharmaceutical industry standards. A low payout ratio means Lilly retains the large majority of its earnings to fund drug development, manufacturing capacity, and growth initiatives while still comfortably covering its dividend.

Cash flow coverage reinforces this view. Lilly generates substantial free cash flow (cash remaining after operating expenses and capital investment), which supports the dividend several times over. The company also maintains a solid balance sheet, with manageable debt relative to its earnings power. These factors, combined with robust demand for its newer medicines, suggest the dividend is well protected and that there is meaningful room for continued increases in the years ahead.

Dividend Compared to Industry Peers

Within the pharmaceutical sector, Lilly's dividend yield is among the lowest of the major players. Large-cap drugmakers such as JNJ (Johnson & Johnson), MRK (Merck), PFE (Pfizer), ABBV (AbbVie), and AMGN (Amgen) generally offer yields ranging from roughly 2% to 5%, while the industry median is above 2%. Lilly's 0.55% yield sits well below that range.

This gap is largely a reflection of valuation: Lilly's share price has appreciated far more rapidly than its dividend. What Lilly lacks in current yield, however, it partly makes up for in growth. Its double-digit annual dividend growth rate exceeds that of many slower-growing, higher-yielding peers, making it a different type of income investment rather than a directly comparable one.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and other market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research and uncover ideas tailored to your strategy.

Is This Stock Attractive for Dividend Investors?

Lilly is best suited to dividend growth investors and long-term investors who prioritize rising income over high current yield. With a yield near 0.55%, the stock offers little immediate cash income, making it a poor fit for investors who depend on dividends for living expenses. However, its low payout ratio, strong free cash flow, and 11-year streak of increases give it a compelling profile for investors seeking compounding income growth over time.

Conservative and income-focused investors may find higher-yielding pharmaceutical peers more appropriate, given the significant gap between Lilly's yield and the industry average. At the same time, the company's earnings momentum and consistent dividend raises suggest the payout could continue growing at an above-average pace. As with any equity, the decision depends on an investor's individual time horizon, income needs, and tolerance for price volatility, and it should be weighed against a diversified portfolio rather than viewed in isolation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations